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Abstract
Background: Rhodium (II) citrate (Rh2(H2cit)4) has significant antitumor, cytotoxic, and cytostatic activity on Ehrlich
ascite tumor. Although toxic to normal cells, its lower toxicity when compared to carboxylate analogues of
rhodium (II) indicates Rh2(H2cit)4 as a promising agent for chemotherapy. Nevertheless, few studies have been
performed to explore this potential. Superparamagnetic particles of iron oxide (SPIOs) represent an attractive
platform as carriers in drug delivery systems (DDS) because they can present greater specificity to tumor cells than
normal cells. Thus, the association between Rh2(H2cit)4 and SPIOs can represent a strategy to enhance the former’s
therapeutic action. In this work, we report the cytotoxicity of free rhodium (II) citrate (Rh2(H2cit)4) and rhodium (II)
citrate-loaded maghemite nanoparticles or magnetoliposomes, used as drug delivery systems, on both normal and
carcinoma breast cell cultures.
Results: Treatment with free Rh2(H2cit)4 induced cytotoxicity that was dependent on dose, time, and cell line.
The IC50 values showed that this effect was more intense on breast normal cells (MCF-10A) than on breast
carcinoma cells (MCF-7 and 4T1). However, the treatment with 50 μM Rh2(H2cit)4-loaded maghemite
nanoparticles (Magh-Rh2(H2cit)4) and Rh2(H2cit)4-loaded magnetoliposomes (Lip-Magh-Rh2(H2cit)4) induced a
higher cytotoxicity on MCF-7 and 4T1 than on MCF-10A (p < 0.05). These treatments enhanced cytotoxicity up
to 4.6 times. These cytotoxic effects, induced by free Rh2(H2cit)4, were evidenced by morphological alterations
such as nuclear fragmentation, membrane blebbing and phosphatidylserine exposure, reduction of actin
filaments, mitochondrial condensation and an increase in number of vacuoles, suggesting that Rh2(H2cit)4
induces cell death by apoptosis.
Conclusions: The treatment with rhodium (II) citrate-loaded maghemite nanoparticles and magnetoliposomes
induced more specific cytotoxicity on breast carcinoma cells than on breast normal cells, which is the opposite of
the results observed with free Rh2(H2cit)4 treatment. Thus, magnetic nanoparticles represent an attractive platform
as carriers in Rh2(H2cit)4 delivery systems, since they can act preferentially in tumor cells. Therefore, these
nanopaticulate systems may be explored as a potential tool for chemotherapy drug development.
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Background
Breast carcinoma represents the major cause of death
among women worldwide. More than 410,000 deaths
are estimated to occur every year, due to its high meta-
static capability [1]. This fact demands a continuous
development of drugs that may effectively treat breast
cancer patients. In point of fact, there is a wide field of
research concerning antitumor activity of metal com-
plexes such as platinum [2], ruthenium [3], and rhodium
[4]. Among these, rhodium carboxylates are known for
their capacity to unpair DNA bases and therefore inhibit
DNA synthesis. Their antitumor effect has already been
studied on Ehrlich ascites tumor, P388 lymphocytic
leukemia, oral carcinoma, L1210 and B16 melanoma, MCa
mammary carcinoma and Lewis lung carcinoma [4-6].
The structure of rhodium (II) citrate (Rh2(H2cit)4), a
rhodium carboxylate, is consistent with the familiar
dimeric “lantern” structure with bridging carboxylates
and a metal-metal bond (Scheme 1). Interestingly, Rh2
(H2cit)4 has significant antitumor, cytotoxic, and cyto-
static activity on Ehrlich ascites tumor [7]. Although
toxic to normal cells, its lower toxicity when compared
to carboxylate analogues of rhodium (II) indicates Rh2
(H2cit)4 as a promising agent for chemotherapy [4].
Nevertheless, few studies have been performed to
explore this potential.
Rh2(H2cit)4 presents uncoordinated functional groups
(-COOH and -OH) in its structure. These groups may
establish physical or chemical interactions when used in
reaction steps with specific molecules or surfaces.
Further, these functional groups are chemically similar
to bioactive molecules that have been used to functiona-
lize nanostructure materials, such as magnetic nanopar-
ticles, leading to stable colloidal suspensions with
excellent biocompatibility and stability [8].
Superparamagnetic particles of iron oxide with appro-
priate surface functionalization/encapsulation, presented
as magnetic fluids or magnetoliposomes, represent an
attractive platform as carriers in drug delivery systems
(DDS) because they can act specifically in tumor cells
[9]. The success of magnetic nanoparticles is mainly due
to their high surface area, capacity to pass through the
tumor cell membrane and retention to the tumor tissue
[10]. In this context, the association between Rh2(H2cit)4
and magnetic nanoparticles, in magnetic fluids or in
magnetoliposomes, may work as target-specific drug
delivery systems, representing a strategy for enhance-
ment of the therapeutic action of Rh2(H2cit)4 without
affecting normal cells.
Some anticancer drugs associated with magnetic nano-
particles such as doxorubicin [11], methotrexate [12],
tamoxifen [13], paclitaxel [14], and cisplatin [15] have
high potential for chemotherapy. Among the magnetic
particles, maghemite (g-Fe2O3) is suitable for clinical
applications due to its magnetic properties and low toxi-
city [16]. In this work, we investigated the cytotoxicity
induced by (1) free Rh2(H2cit)4, (2) Rh2(H2cit)4-loaded
maghemite nanoparticles (Magh-Rh2(H2cit)4) and (3)
Rh2(H2cit)4-loaded magnetoliposomes (Lip-Magh-Rh2
(H2cit)4) on both normal and carcinoma breast cell
cultures.
The association of Rh2(H2cit)4 to magnetic nanoparti-
cles induced specific cytotoxic effect in carcinoma cells.
Therefore, we suggest that Magh-Rh2(H2cit)4 and Lip-
Magh-Rh2(H2cit)4 may be explored as potential drugs
for chemotherapy.
Results
• Characterization of rhodium (II) citrate
Elemental analyses of rhodium (II) citrate sample are
consistent with the molecular formula [Rh2(C6H7O7)4
(H2O)2] and suggest, in solid state, the presence of two
water molecules in axial position. Thermal studies of the
complex showed that the temperature ranged from 25
to140°C, with an estimated mass loss 4.1% (calculated
mass loss = 3.6%), which can be accounted for by the loss
of the two water molecules. The ESI-MS spectrum of
[Rh2(C6H7O7)4+H]
+ (Figure 1A) shows prominent peaks
at m/z = 970.8, corresponding to [Rh2(C6H7O7)4 + 1H]
+.
The complex was observed in a 13C NMR spectrum
(Figure 1B) where the signals of a- and b-carboxyl car-
bon atoms in the complex (195.3 and 192.8 ppm,
respectively) appear shifted in comparison with those
with free ligands (179 and 176.5 ppm, respectively). The
shift and split of observed C-O stretching frequencies
Scheme 1 Schematic representation of rhodium (II) citrate showing
the possible coordination of the rhodium dimer to the citric acid by
the a- and b-carboxyl groups. R groups represent the side chains of
citrate ligand
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(from 1740 to 1592 and 1412 cm-1) of citric acid in
infrared spectra has been used to show the coordination
of citric acid to rhodium. The value of Δ(νas CO2 - νs
CO2) = 184 cm
-1 observed in the spectrum of rhodium
(II) citrate suggests the occurrence of a bridged or che-
lated bidentate coordination.
The titration of free carboxylic acid groups in the
complex provided a ratio of 7.4 ± 0.4 mol H+ by com-
plex mol, indicating a 8:1 stoichiometry predicted by the
proposed formula Rh2(H2cit)4.
• Characterization of Magnetic Nanoparticles and
Magnetoliposomes
SPIOs were obtained in the maghemite (g-Fe2O3) phase
and presented the characteristic diffraction patterns of
inverse spinel structure when compared to reference
patterns in the literature [17] for maghemite from the
International Center of Diffraction Data [18] (Figure
2A). The molar ratio of Fe2+/Fe3+ obtained by elemental
analysis was less than 0.015, revealing an efficient oxida-
tion from magnetite to maghemite phase.
The magnetization curves for bare maghemite (Magh)
and surface modified maghemite (Magh-Rh2(H2cit)4) are
shown in Figure 2B. For both samples, the curves indicate
superparamagnetic behavior, since no hysteresis was
observed [19,20]. The saturation of magnetization was
48 emug-1 to Magh and 45 emug-1 to Magh-Rh2(H2cit)4.
The surface modification of maghemite nanoparticles
was evidenced by infrared spectroscopy and zeta poten-
tial measurements. The infrared spectra of functionalized
nanoparticles (Figure 2C) show intense absorptions in
1630 and 1564 cm-1 assigned to asymmetrical νas(COO)
and symmetrical νs(COO) stretching modes of carboxy-
late groups [21]. These bands indicate the chemical
adsorption of Rh2(H2cit)4 molecules onto the oxide sur-
face [22]. In 1724 cm-1, the stretching vibration of car-
boxylic acid ν(C = O) is observed.
The presence of free acid groups is consistent with
obtainment of stable magnetic fluids in physiological
pH. The surface Magh-Rh2(H2cit)4 presented a nega-
tive zeta potential in a broad range of pH values, and
its magnitude in pH 7 was about -35 mV (Figure 2D).
Figure 1 A) Positive ion ESI-MS spectra of rhodium (II) citrate: [Rh2(C6H7O7)4+H]
+ (m/z 970,8). Ordinate: relative intensity. B) 13C NMR
spectra of Rh2(H2Cit)4 complex. The upper detail shows that the signals of a- and b-carboxyl carbon atoms in the complex (195.3 and 192.8
ppm, respectively) appear shifted.
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The complex and iron oxide content in the sample
Magh-Rh2(H2cit)4 were 1.4 mmolL
-1 and 0.33 molL-1,
respectively.
The magnetoliposome size presented an average mea-
surement of 101.8 ± 0.1 nm, with polydispersion index
lower than 0.22, which corresponded to 98% of the
Gaussian distribution (Figure 3).
TEM micrographs revealed that the maghemite
nanoparticles used (Magh-Rh2(H2cit)4) have a spherical
shape (Figure 4A) and a modal diameter of 7.85 nm
(SD = 2.10) (Figure 4B). In contrast, samples of Lip-
Magh-Rh2(H2cit)4 have a rounded shape (Figure 4C)
and a modal diameter of 28.19 nm (SD = 6.17) (Figure
4D). Different sized nanoparticles were also observed
in the samples, demonstrating their polydispersed
distribution.
• Cytotoxicity of free rhodium (II) citrate
The distribution of cell viability according to the treat-
ment, time, and the evaluated cell line after incubation
with free rhodium (II) citrate (Rh2(H2cit)4) is shown in
Table 1. A significant difference in the viability of the
cells with and without Rh2(H2cit)4 treatment was
observed, independently of the cell line and the duration
of treatment (p < 0.05). We did not observe cytotoxicity
at doses lower than 50 μM Rh2(H2cit)4 (data not
shown). All cell lines presented similar cytotoxic effect
of 50 μM Rh2(H2cit)4 after 24, 48, and 72 h treatments.
However, at doses higher than 200 μM, higher cytotoxi-
city was observed on breast normal cell line (MCF-10A)
than on breast carcinoma cell lines (MCF-7 and 4T1).
In general, the cytotoxic effect of Rh2(H2cit)4 was higher
after 72 h and after treatments with 500 and 600 μM
doses (p < 0.05). Thus, Rh2(H2cit)4 induced a dose and
time-dependent viability reduction on the investigated
cell lines.
Figure 2 A) Diffraction pattern for sample Magh. B) Magnetization curves at 300 K for bare: ○ maghemite (Magh), and ● modified
maghemite (Magh-Rh2(H2cit)4). C) Infrared Spectra for ___ Magh and - - - Magh-Rh2(H2cit)4; D) Zeta potential versus pH curves for □ ○ □ Magh,
and □ ● □ Magh-Rh2(H2cit)4.
Figure 3 Size analysis of the magnetoliposomes (1.96 × 1015
iron particles/mL) by laser light scattering.
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Paclitaxel (50 μM), used as positive control, induced a
more intense cytotoxic effect after 72 h in the three cell
lines than Rh2(H2cit)4. Treatments with DMSO caused
no significant cytotoxicity to the three cell lines studied
after 24 and 48 h treatments. Nevertheless, after 72 h,
DMSO demonstrated a higher cytotoxicity to 4T1 and
MCF-10A cells lines than to MCF-7 line. Since the cells
studied showed sensitivity to paclitaxel our experimental
models were validated (Table 1).
The IC50 values of the treatments with Rh2(H2cit)4 in
MCF-7, 4T1, and MCF-10A cells are shown in Table 2.
The results confirmed that the cytotoxicity of the
Figure 4 Morphological characterization and measurement of nanoparticles by transmission electron microscopy. A) Electron
micrograph of maghemite nanoparticles associated with rhodium (II) citrate (Magh-Rh2(H2cit)4, final concentration: 3.12 × 10
13 iron particles/mL).
B) Histogram of the distribution of the measured diameters of Magh-Rh2(H2cit)4, with a modal diameter mean of 7.85 nm and s mean = 2.10. C)
Electron micrograph of magnetoliposomes associated with rhodium (II) citrate (Lip-Magh-Rh2(H2cit)4, final concentration: 1.25 × 10
13 iron
particles/mL). D) Histogram of the distribution of diameters of Lip-Magh-Rh2(H2cit)4 showing a mean modal diameter of 28.19 nm and mean
s = 6.17.
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treatment with the complex is dependent on dose, time,
and cell line. The IC50 values for human carcinoma
(MCF-7) and mouse carcinoma (4T1) cell lines were
relatively similar. Likewise, normal cell lines (MCF-10A)
were more sensitive to treatment with Rh2(H2cit)4
(Table 2).
• Analysis of morphological and structural alterations on
MCF-7 and 4T1 cell lines
MCF-7 cells have predominantly fusiform morphology
(Figure 5A), while 4T1 cells presented both spindle and
rounded cells forming clusters, characteristic of this
these types of tumor cells (Figure 6A). Nevertheless,
both MCF-7 and 4T1 cells became more rounded and
with blebbing after treatment with 500 μM Rh2(H2cit)4
for 48 h. After this treatment smaller confluence and
reduced cell size were also observed when 4T1 and
MCF-7 control cells were compared. Furthermore, this
effect was more pronounced in the 4T1 cell line (Figure
5A, B and 6A, B). No morphological alterations were
observed in MCF-7 and 4T1 untreated cells (control),
according to the images taken by the phase contrast
microscope (Figure 5A and 6A).
Ultrastructural details of MCF-7 and 4T1 cell mor-
phology, after treatment with 500 μM Rh2(H2cit)4, are
shown in Figure 5D, F and 6D, F, respectively. After this
treatment, several morphological alterations were
observed, such as the presence of blebbing, the
Table 1 Distribution of cell viability percentage according to the treatment, cell line and exposure time
Treatment Cell line 24 h 48 h 72 h
0 (control) MCF-7 100.00 ± 1.50 A*; a# 99.94 ± 1.95 A; a 100.00 ± 1.06 A; a
4T1 100.00 ± 1.21 A; a 100.00 ± 1.46 A; a 100.00 ± 1.34 A; a
MCF-10A 100.00 ± 3.30 A; a 100.00 ± 1.05 A; a 100.00 ± 0.92 A; a
Rh2(H2cit)4 50 μM MCF-7 94.96 ± 2.44 A; a 97.48 ± 2.84 A; a 81.19 ± 2.30 B; a
4T1 90.31 ± 1.38 A; a 87.79 ± 2.63 A.B; a 81.42 ± 2.56 B; a
MCF-10A 97.75 ± 3.77 A; a 97.82 ± 1.40 A; a 84.30 ± 2.55 B; a
Rh2(H2cit)4 200 μM MCF-7 89.28 ± 2.60 A; a 81.64 ± 2.38 A; a 70.13 ± 2.58 B; a
4T1 79.13 ± 1.44 A; b 73.42 ± 2.17 A.B; a 68.12 ± 3.64 B; a
MCF-10A 61.82 ± 6.54 A; b 44.19 ± 1.60 B; b 30.43 ± 2.69 C; b
Rh2(H2cit)4 300 μM MCF-7 85.33 ± 2.14 A; a 73.77 ± 2.58 B; a 54.14 ± 2.47 C; a
4T1 73.95 ± 2.54 A; a 61.77 ± 1.47 B; b 47.79 ± 4.11 C; a
MCF-10A 39.41 ± 7.47 A; b 23.81 ± 0.74 B; c 12.78 ± 0.92 C; b
Rh2(H2cit)4 500 μM MCF-7 50.08 ± 2.49 A; a 25.29 ± 3.46 B.C; a 30.39 ± 3.47 C; a
4T1 46.14 ± 3.49 A; a 30.66 ± 1.22 B; a 26.07 ± 2.75 B; a
MCF-10A 25.85 ± 6.46 A; b 11.62 ± 1.17 A.B; b 5.46 ± 0.46 C; b
Rh2(H2cit)4 600 μM MCF-7 28.71 ± 3.90 A; a 16.86 ± 1.77 B; a 12.16 ± 1.93 B; a
4T1 29.87 ± 3.67 A; a 15.86 ± 0.57 B; a 9.97 ± 1.49 B; a
MCF-10A 13.34 ± 2.43 A; b 10.26 ± 1.27 A; b 4.76 ± 0.39 B; b
DMSO (0.85%) MCF-7 90.51 ± 5.9 A; a 90.93 ± 1.7 A; a 96.4 ± 1.4 A; a
4T1 106.2 ± 1.3 A; b 100.6 ± 2.97 A; a 43.07 ± 8.2 B; b
MCF-10A 148.1 ± 6.8 A; c 82.45 ± 2.3 B; a 63.35 ± 2.2 C; c
Paclitaxel 50 μM MCF-7 70.07 ± 0.4 A; a 55.93 ± 1.6 B; a 18.92 ± 4.3 C; a
4T1 68.31 ± 1.2 A; a 30.12 ± 0.7 B; b 21.51 ± 1.4 C; a
MCF-10A 80.17 ± 6.7 A; c 33.52 ± 1.09 B; b 20.95 ± 1.1 C; a
The data represent the mean ± SE (mean standard error) of three independent experiments in triplicates. * Different capital letters denote statistical difference
between viability in the different times (rows) for a given cell line (breast cancer cells MCF-7. 4T1 or normal cells MCF-10A) under the same treatment (p <0.05).
# Different tiny letters indicate mean statistical difference between the viability of different cell lines (columns) for a given time (24. 48 or 72 hours) (p <0.05).
Table 2 Distribution of the IC50 values and their respective confidence intervals (95%) in MCF-7, 4T1, and MCF-10A
cell lines after treatment with free rhodium (II) citrate (Rh2(H2cit)4)
IC50 (IC 95%)
Cell lines 24 hours 48 hours 72 hours
MCF-7 483 μM (459,2 a 507 μM) 376 μM (356,2 a 396,1 μM) 294 μM (259,9 a 332,5 μM)
4T1 440 μM (407,3 a 475 μM) 337 μM (317,3 a 357,8 μM) 271 μM (241,4 a 303,9 μM)
MCF-10A 250 μM (211,1 a 295,2 μM) 181 μM (172,3 a 190,8 μM) 123 μM (114,7 a 132,7 μM)
These data refers from viability of cells after treatment with Rh2(H2cit)4 (50-600 μM) for 24, 48 and 72 hours.
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segregation of condensed chromatin to nuclear periph-
ery and the remarkable presence of vacuoles and con-
densed mitochondria when compared to the MCF-7 and
4T1 control cells (Figure 5C-F and 6C-F), respectively.
These morphological changes can be related to the
apoptotic events.
• Phosphatidylserine exposition on breast carcinoma cells
In Figure 7 the percentage of cells that were positively
stained for annexin V-FITC is represented. After
500 μM Rh2(H2cit)4 treatment, the annexin-V
+ cell
number (%) was significantly higher than that of the
control in both cell lines (p < 0.05). After this treatment,
Figure 5 Morphological and structural changes induced by rhodium (II) citrate (Rh2(H2cit)4) in MCF-7 breast carcinoma cell line after
48 hours of treatment. Cells were incubated with 500 μM Rh2(H2cit)4 for 48 hours and examined by phase contrast microscopy (A, B) and
transmission electron microscopy (C-F). (A, C and E) control (cells without treatment); (B, D and F) cells treated with 500 μM of Rh2(H2cit)4.
Differences were observed in cell morphology, vacuole amount and mitochondrial condensation between untreated cells (A, C and E) and Rh2
(H2cit)4 treated cells (B, D and F). Legends: blebbing (arrows), vacuoles (arrow heads), nucleus (n), mitochondria (m), condensed chromatin (*).
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there was a 25% and a 38% increase of annexin-V+ cell
number in MCF-7 and 4T1, respectively (p < 0.05), thus
revealing that the 4T1 cell line was more sensitive to
treatment with Rh2(H2cit)4 (500 μM). No difference in
the percentage of annexin-V+ cell number was observed
in relation to untreated cells (control) and 50 μM Rh2
(H2cit)4 treated cells, in both cell lines (p < 0.05).
• Analysis of nuclear fragmentation and actin alterations
MCF-7 cells without treatment (control) showed orga-
nized spread actin in the cytoplasm and interactions
between surrounding cells through membrane projec-
tions supported by actin (Figure 8A). After treatment
with 50 μM Rh2(H2cit)4, slight nuclear condensation
and reduction of actin filaments were observed
Figure 6 Morphological and structural changes induced by rhodium (II) citrate (Rh2(H2cit)4) in 4T1 breast carcinoma cell line after
48 hours of treatment. Cells were incubated with 500 μM Rh2(H2cit)4 for 48 hours and examined by phase contrast microscopy (A, B) and
transmission electron microscopy (C-F). (A, C and E) control (cells without treatment); (B, D and F) cells treated with 500 μM of Rh2(H2cit)4.
Differences were observed in cell morphology, vacuole amount and mitochondrial condensation between untreated cells (A, C and E) and Rh2
(H2cit)4 treated cells (B, D and F). Legends: blebbing (arrows), vacuoles (arrow heads), nucleus (n), mitochondria (m), condensed chromatin (*).
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(Figure 8C). Nevertheless, a noticeable reduction in
actin and increased nuclear condensation were
observed after treatment with 500 μM (Figure 8E). In
general, the cells treated with Rh2(H2cit)4 showed a
loss of cytoplasmic projections when compared to the
control cells (Figure 8A, C and 8E). Furthermore, the
cells treated with paclitaxel (50 μM) showed nuclear
condensation and fragmentation and a lower amount
of actin cytoskeleton, similar to those treated with Rh2
(H2cit)4 (Figure 8G). Phase contrast images were
shown to validate DAPI and phalloidin-Alexa Fluor
488 staining for each experimental group (Figure 8B,
D, F and 8H).
• Cytotoxicity of rhodium (II) citrate-loaded magnetic
nanoparticles
MCF-7, 4T1, and MCF-10A cell viabilities were similar
after treatment with 50 μM of free Rh2(H2cit)4, indepen-
dent of the treatment duration (Figure 9). Nevertheless,
treatment with 50 μM Rh2(H2cit)4-loaded maghemite
nanoparticles (Magh-Rh2(H2cit)4) and Rh2(H2cit)4-
loaded magnetoliposomes (Lip-Magh-Rh2(H2cit)4)
induced a significant decrease, mainly in MCF-7 and
4T1 breast carcinoma cell viability (p < 0.05). This effect
was more evident in 4T1 cells, which showed a fall in
viability of 46% (± 2.7), 69% (± 2), and 74% (± 1.4) after
Magh-Rh2(H2cit)4 treatment for 24, 48, and 72 h,
respectively. Within the same time frame, the Lip-
Magh-Rh2(H2cit)4 treatment decreased 4T1 cell viability
by 57% (± 1.3), 68% (± 2.4), and 84% (± 2.9) after 24, 48
and 72 h treatments, respectively (Figure 9). In contrast,
the same dose of free Rh2(H2cit)4 reduced cell viability
by about 10% (± 1.4), 12% (± 2.6), and 18% (± 2.6), after
Figure 7 Phosphatidylserine exposure induced by rhodium (II)
citrate (Rh2(H2cit)4) in breast carcinoma cells (lines 4T1 and
MCF-7) after 48 hours of treatment. Cells were stained with
annexin V-FITC (fluorescein-5-isothiocyanate) and PI (propidium
iodide) and analyzed by flow cytometry. The percentage of annexin
positive cells represents the cells with exposed phosphatidylserine.
Data were normalized with the control (cells without treatment)
and expressed as percentage of the mean ± SE of three
experiments that were independently performed in triplicate. One
or two asterisks (* and **) indicate statistical differences between
control and cells treated in MCF-7 and 4T1 cell lines, respectively
(p < 0.001).
Figure 8 Nuclear fragmentation and reduction of actin
filaments in MCF-7 breast carcinoma cells 48 hours after
treatment. Cells were stained with DAPI (4’,6-diamidino-2-fenilindol)
to visualize the nucleus (in blue) and with Phalloidine-Alexa Fluor
488 to visualize actin (in green). (A, B) control (cells without
treatment); (C, D) cells treated with 50 μM and (E, F) with 500 μM of
Rh2(H2cit)4; (G, H) cells treated with 10 nM paclitaxel for 2 h. Arrows
and arrow heads indicate nuclear fragmentation and chromatin
condensation, respectively. Phase-contrast images are presented for
validation of fluorescence (Figure 8B, D, F, H).
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24, 48 and 72 h treatments, respectively (p < 0.05).
However, 72 h of Magh-Rh2(H2cit)4 and Lip-Magh-Rh2
(H2cit)4 treatments on 4T1 cells induced a decrease in
cell viability of respectively 74% (± 1.4) and 84% (± 2.9)
against 18% (± 2.6) presented by the free drug at the
same concentration. Thus, Magh-Rh2(H2cit)4 and Lip-
Magh-Rh2(H2cit)4 treatments showed enhanced Rh2
(H2cit)4 potency of up to 3.9 and 4.6 times, respectively.
Longer treatments enhanced the cytotoxicity of both
Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 (Figure 9).
After 24 h of treatment with Magh-Rh2(H2cit)4 and Lip-
Magh-Rh2(H2cit)4, a differential cytotoxicity was observed
among the three cell lines. This effect was more pro-
nounced in 4T1 and MCF-7 cells. Further, we observed
that Lip-Magh-Rh2(H2cit)4 treatment was more cytotoxic
than Magh-Rh2(H2cit)4 to MCF-7 cell line (p < 0.05).
A higher cytotoxicity was noticed in MCF-10A 72 h after
the Magh-Rh2(H2cit)4 treatment, but this did not happen
with the Lip-Magh-Rh2(H2cit)4 treatment. It is noteworthy
that in all time windows and all tested cell lines there was
no difference in the viability of the control cells (p < 0.05)
(Figure 9).
The cells treated with maghemite nanoparticles with-
out rhodium (II) citrate (Magh) showed no reduction in
viability after any treatment duration; however, viability
reduction was observed after 72 h treatment with Lip-
Magh (data not shown).
Discussion
In this work, the rhodium (II) citrate was isolated from
the aqueous solution as powder and not as a single crys-
tal. Due to this fact the complete structure determination
cannot be resolved. However, the elemental analysis, 13C
NMR, IR, UV/Visible data enable us to predict that the
compound structure was similar to the previously studied
rhodium (II) carboxylates [23]. In the 13C NMR spectrum
(Figure 1B), the signals of a- and b-carboxyl carbon
atoms in the complex appear shifted in comparison with
Figure 9 Cytotoxic effect of maghemite nanoparticles associated with rhodium (II) citrate (Magh-Rh2(H2cit)4) and magnetoliposomes
(Lip-Magh-Rh2(H2cit)4) in breast carcinoma cell lines (MCF-7 and 4T1) and breast normal cell line (MCF-10A). Cells were incubated with
free rhodium (II) citrate (Rh2(H2cit)4), Magh-Rh2(H2cit)4 (final concentration: 3 × 10
15 iron particles/mL and 23 mM of iron) or Lip-Magh-Rh2(H2cit)4
(final concentration: 12.5 × 1015 iron particles/mL and 94.5 mM of iron) for 24, 48 and 72 h. In all treatments the concentration of Rh2(H2cit)4
used was 50 μM. Data were normalized with the control (cells without treatment) and expressed as mean ± standard error of two independent
experiments performed in triplicates. Different letters indicate statistical difference within each treatment (p < 0.05).
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those for the free ligand, showing that the citrate anion is
coordinated through these two carboxyl groups. In the
carbinol carbon atoms, however, only a small shift is
observed, indicating that there is no participation of this
group in coordination [24,25]. Evidence of the coordina-
tion of citric acid ligand to rhodium though its carboxyl
group was also obtained by infrared spectra, and it was
similar to that reported by Najjar and co-workers for rho-
dium (II) citrate [26]. The coordination by the two differ-
ent carboxyl groups suggests the formation of five
isomeric structures; however, for the development of this
work these hypothetic isomers were not separated.
The crystalline structure of magnetic nanoparticles
could be confirmed by X-ray difractometry as maghe-
mite phase. According to Magh and Magh-Rh2(H2cit)4
magnetization curves profile (Figure 2B), the nanoparti-
cles present superparamagnetic behavior at room tem-
perature and saturation magnetization close to values
already published in the literature for 7 nm maghemite.
The effect of the complex on the particle’s surface to
saturation magnetization is negligible [27].
Surface functionalization of SPIO with rhodium (II)
citrate produced deep changes in the nanoparticles’ phy-
sical-chemical properties. These changes were evidenced
by infrared spectroscopy and zeta potential measure-
ments, as well as by saturation of magnetization. The
infrared spectra of Magh-Rh2(H2cit)4 (Figure 2C)
showed intense absorptions assigned to asymmetrical νas
(COO) and symmetrical νs(COO) stretching modes of
carboxylate groups [21], indicating the chemical adsorp-
tion of Rh2(H2cit)4 molecules into the oxide surface
[22]. Zeta potential versus pH measurements indicated
an isoelectric point (iep) at about pH 3. The zeta poten-
tial becomes negative in the range of pH above 3 and its
magnitude at pH 7 is about -38 mV. This zeta potential
value shows that the particles are negatively charged
and indicates an efficient electrostatic stabilization.
It is well known that the magnetic properties of nano-
materials are dependent on their size. Particles smaller
than 10 nm, besides having high magnetic applicability,
are also ideal to avoid recognition by the mononuclear
phagocyte system and, thus, stay longer in the bloodstream
[16]. Considering the particle size, Magh-Rh2(h2cit)4 has
potential for applications in the biological system as it pre-
sents a modal diameter of 7.5 nm. Moreover, considering
the magnetoliposome size, as determined by zetasizer
equipment (Figure 3), we could conclude that the small
lipid bilayer vesicle will increase the interaction of the
active compounds with cells as a normal behavior of other
liposomal drug delivery systems (DDS) of similar size car-
rying similar nanoparticles to the cellular target [28].
In our in vitro study, we observed that cell lines
MCF-7, 4T1, and MCF-10A exhibited cytotoxicity when
treated with Rh2(H2cit)4. It is reported that others
carboxylates such as acetate, butyrate, and propionate of
rhodium, in association with isonicotinic acid, also
induces cytotoxicity in tumor cells (K562 leukemia cell
line) [29]. We also observed that Rh2(H2cit)4 cytotoxicity
was dose and time dependent. High concentrations of
Rh2(H2cit)4 (up to 200 μM) were seen to induce greater
cytotoxicity after longer treatments (72 hours). Further-
more, it was also demonstrated that its cytotoxic effect
differed between breast normal (MCF-10A) and breast
carcinoma (4T1 and MCF-7) cell lines, being more pro-
nounced in breast normal cells (Table 1 and 2). Our
data are, therefore, in agreement with a number of
other preliminary studies. For instance, preliminary stu-
dies showed that rhodium (II) citrate induces a higher
cytotoxicity, with increasing dose and duration of treat-
ment, on breast carcinoma cells (Ehrlich) and on carci-
noma (Y-1) and normal adrenocortical cells (AR-1(6))
[7]. Similarly, it was also reported that other rhodium
carboxylates such as acetate, methoxyacetate, propio-
nate, and butyrate inhibited the proliferation of leukemia
cells (L1210), inducing cytotoxic effects in a dose and a
time-dependent manner [30].
Several studies reported promising antitumor activities
of rhodium carboxylates in mouse bearing Ehrlich breast
carcinoma, but their clinical use has been limited
because they showed toxicity in normal cells [4,31]. In
our study, Rh2(H2cit)4 was also cytotoxic to in vitro nor-
mal cells. The IC50 values (Table 2) showed that Rh2
(H2cit)4 cytotoxic effect was more intense on breast nor-
mal cells (MCF-10A) than on breast carcinoma cells
(MCF-7 and 4T1). However, according to the IC50
values (Table 2), we demonstrated that rhodium (II)
citrate is less toxic to normal cells than are members of
the lipophilic complex, such as propionate, butyrate, and
acetate of rhodium [30]. Therefore, this complex may
have a higher chemotherapeutic potential in relation to
other carboxylates. The distinctness of cytotoxicity
among lipophilicity por hydrophilicity carboxylates
could be explained by the differences among their prop-
erties, such as chain length and hydrophilicity of parts
of the molecules [4].
The cytotoxic activity of some rhodium carboxylates is
given by their ability to bind covalently to DNA bases,
unpairing them, and subsequently inhibiting DNA repli-
cation and transcription [5,7]. It was reported that rho-
dium carboxylates establish adducts through their axial
ligands with electron donor atoms, preferably N, S, O,
and P, from molecules such as adenine, cysteine, and
RNase A [32]. Moreover, enzymes with free thiol groups
(-SH) are known to interact irreversibly with these
metal complexes [30]. This interaction could explain the
inactivation of some essential DNA replication enzymes
which result in their damage. Thus, Rh2(H2cit)4 is toxic
to both normal and carcinoma cells since they need
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DNA replication and transcription to survive. Zyngier
and colleagues [7] demonstrated that Rh2(H2cit)4 inhib-
ited DNA synthesis of breast carcinoma (Ehrlich), and
also of carcinoma (Y-1) and, normal adrenocortical cells
(AR-1(6)). We observed fragmentation nucleus induced
by Rh2(H2cit)4 (Figure 5D and 6D, Figure 8C and 8E).
These observations suggest that Rh2(H2cit)4 not only
induces DNA fragmentation on MCF-7 and 4T1 cells,
but may also prevent their DNA synthesis.
According to our TEM observations, the MCF-7 and
4T1 cells exhibited condensed mitochondria after Rh2
(H2cit)4 treatment (Figure 5D, F and 5F), indicating that
this organelle is somehow affected by the complex. This
condensed mitochondria phenotype can be associated
with a drop in the mitochondrial membrane potential
related to the cell death process [33].
We observed that Rh2(H2cit)4 induced an increase in
the number of vacuoles compared to the untreated cells,
as shown in TEM (Figure 5 and 6). It can indicate a
degradation pathway related to the response to meta-
bolic stress or microenvironmental conditions to ensure
energy balance. Moreover, this increase has been impli-
cated in the cell death process [34,35].
After 48 h of treatment with 500 μM Rh2(H2cit)4, an
increase of annexin-V+ breast carcinoma cells was
observed (Figure 7). The presence of annexin-V+ in cells
is related to apoptotic events, since it indicates the
exposure of phosphatidylserine outside the inner mem-
brane. The actin analysis performed by confocal micro-
scopy showed a dose-dependent disassembly of the actin
cytoskeleton after Rh2(H2cit)4 treatment in the MCF-7
cell (Figure 8). Furthermore, there was a notable reduc-
tion in intercellular communication, possibly caused by
changes in the actin cytoskeleton (Figure 8). This struc-
ture is an important target for many antitumor drugs
since it plays a crucial role in maintaining cell morphol-
ogy, mitosis, signaling regulation for cell survival, and
cell motility [36-38]. We demonstrated that the reduc-
tion of actin after Rh2(H2cit)4 treatment (500 μM) is
intrinsically related to the higher cytotoxicity of this
complex in MCF-7 cells (Table 1 and Figure 8).
In summary, Rh2(H2cit)4 induces alterations in the
treated cells that are related to the apoptosis process,
such as nuclear fragmentation, blebbing, disassembly of
the actin cytoskeleton, and phosphatidylserine exposure
in the plasma membrane. These features suggest that
Rh2(H2cit)4 has potential as an efficient chemotherapic
agent since targeting of chemotherapeutic agents is
related to its capacity to induce apoptosis.
In order to reduce the toxicity of Rh2(H2cit)4 for nor-
mal cells while enhancing the efficacy in carcinoma
therapy, we proposed its association with magnetic
nanoparticles. Doses of 50 μM of Rh2(H2cit)4-loaded to
maghemite nanoparticles and to magnetoliposomes were
more cytotoxic than the equimolar dose of free Rh2
(H2cit)4. Besides, the treatment with 50 μM of Magh-
Rh2(H2cit)4 induced cytotoxicity similar to a tenfold
dose of the free complex on carcinoma cells. In addi-
tion, the Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4
induced time-dependent cytotoxic effect like those of
free Rh2(H2cit)4. After 72 h, for example, Magh-Rh2
(H2cit)4 and Lip-Magh-Rh2(H2cit)4 treatments enhanced
cytotoxicity potency up to 3.9 and 4.6 times, respec-
tively. More importantly, MCF-7 and 4T1 carcinoma
breast cells were more susceptible to Magh-Rh2(H2cit)4
and Lip-Magh-Rh2(H2cit)4 treatments than MCF-10A
normal breast cells, differently from what is observed
with free Rh2(H2cit)4 (Table 2 and Figure 9).
Carcinoma and normal cells present different metabo-
lism in relation to iron uptake. The metabolism of breast
carcinoma cells, for example, is faster than in normal cells.
Consequently, carcinoma cells require larger amounts of
micronutrients, particularly iron, which can be evidenced
by the presence of more transferrin receptors in these
[39]. In this way, an increased iron uptake by tumor cells
could result in a selective uptake and a higher retention of
Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 in relation
to free Rh2(H2cit)4 complex. Additionally, magnetic nano-
particle uptake by carcinoma cells may also be associated
with the amino group’s coverage of nanoparticles [40].
The literature reports that free thiol groups (-SH) interact
with the rhodium carboxylates, which are rich in car-
boxylic groups [30]. Therefore, the carboxylic groups pre-
sent in Magh-Rh2(H2cit)4 citrate molecules could improve
the transport of nanoparticles through the cell membrane
via the proteic thiol groups.
Although rhodium (II) citrate-coated maghemite
nanoparticles seem not to have been described before,
the association of rhodium complex with polymeric
microspheres of hydroxy-propyl-cyclodextrin [41] and
with cyclodextrins from hydroxyapatite has been
reported [42]. These associations were shown to repre-
sent a promising alternative in the minimization of the
nonspecific toxicity of these agents, mainly because they
increase the efficiency of encapsulation and the duration
of rhodium (II) citrate release. Our study demonstrated
that the composition of maghemite nanoparticles coated
with citrate or rhodium (II) citrate was appropriate for
its application as a drug delivery system. Coating with
the citrate molecule was able to stabilize our magnetic
nanoparticles and also was not toxic to the investigated
cells (data not shown). Citrate-functionalized-maghemite
has been attested as providing successful nanoparticles
in the production of biocompatible and stable magnetic
fluids [43,44]. Furthermore, citrate-functionalized-
maghemite was also shown to be internalized by in vitro
human melanoma cells (SKMEL 37) with no significant
cytotoxicity even when cultivated for 72 h [45].
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We demonstrated that Magh-Rh2(H2cit)4 and Lip-
Magh-Rh2(H2cit)4 compositions reduced more efficiently
the viability of MCF-7 and 4T1 breast carcinoma cells
than the free Rh2(H2cit)4 treatment. Furthermore, it is
important to emphasize that the cytotoxicity induced by
both Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 was
greater in tumor cells than normal ones, since no cyto-
toxicity was observed after treatment with Magh. In
addition, if these nanosystems were associated to target
molecules for breast carcinoma cells such as folic acid,
for instance, their potential for selective uptake would
be even higher [46]. Thus, Magh-Rh2(H2cit)4 and Lip-
Magh-Rh2(H2cit)4 have much potential for application
in drug delivery systems, and they should be considered
as a platform to enhance Rh2(H2cit)4 cytotoxicity, speci-
fically in breast carcinoma.
Conclusions
We showed that Rh2(H2cit)4 induces significant cyto-
toxic effects, especially after longer treatments and at
higher concentrations. These effects were related to sev-
eral structural and morphological alterations, probably
coming from cell death by apoptosis and autophagy.
Further, higher cytotoxicity in the MCF-10A breast nor-
mal cell line was noted than in the 4T1 and MCF-7
breast cancer cell lines. Nonetheless, the Magh-Rh2
(H2cit)4 and Lip-Magh-Rh2(H2cit)4 treatments were
more selective to breast cancer cells with up to 4.6
times enhanced potency in comparison to the free Rh2
(H2cit)4. Therefore, we suggest that Magh-Rh2(H2cit)4
and Lip-Magh-Rh2(H2cit)4 should be considered a suita-
ble and effective platform for drug delivery systems that
operate more specifically in tumor cells.
Methods
Materials
All solvents and reagents related to the synthesis of Rh2
(H2cit)4 and Magh-Rh2(H2cit)4 are of analytical grade
and were used without further purification: iron(II)
chloride tetrahydrate (Acros); iron (III) chloride hexahy-
drate (Ecibra); hydrated rhodium (III) chloride (Sigma-
Aldrich); citric acid (Vetec), and sodium hydroxide
(FMaia). The rhodium(II) trifluoroacetate, [Rh2(tfa)4],
was prepared following a previously reported procedure
[47].
• Characterization of Rhodium Compounds
Infrared spectra were recorded using KBr pellets on a
Bomem BM100 FT-IR spectrometer in the 4000-500 cm-1
region. Elemental analyses were carried out on a Perkin-
Elmer 2400 analyzer. Rhodium concentrations were mea-
sured in Spectro Ciros CCD ICP-AES spectrometer. The
samples were digested with concentrated HCl in an aqu-
eous solution. Electronic spectra were recorded in the
800-200 nm range on Beckman DU70 spectrometer in
water solution. The 13C NMR spectra (carbon-13 nuclear
magnetic resonance spectroscopy) were obtained at room
temperature in D2O using a Bruker Avance III 500 spec-
trometer, operating at a frequency of 125.75 MHz. The
13C chemical shifts were measured relative to TMS (tetra-
methylsilane) measurements. TGA (thermogravimetric
analysis) was performed at a heating rate of 10°C min-1 in
the temperature range of 25-1000°C, under nitrogen flow
of 10 mL min-1 using a Shimadzu DTG-60 instrument
and standard aluminum crucible. The ESI mass spectra
(Electrospray ionisation-mass spectrometry) were acquired
using a Bruker Daltonics Esquire 3000 Plus mass spectro-
meter in capillary exit voltage set at 4 kV and the desolva-
tion chamber temperature was set to 280°C.
Potentiometric titration of an aqueous solution of Rh2
(H2cit)4 0.0051 molL
-1 was performed in triplicate using a
0.046 molL-1 NaOH solution as titrant.
• Characterization of Magnetic Nanoparticles
X-ray powder diffraction (XRD) data were collected by a
XRD-6000 diffractometer. The magnetization of the iron
oxide nanoparticles was measured at room temperature
using a vibrating-sample magnetometer (EV9-VSM
AdMagnets). The iron concentration in the fluids was
determined by the method of o-phenanthroline [48].
Solution absorbances were measured at 512 nm in a
Hitachi U1100. Zeta potential was obtained from elec-
trophoretic mobility (em) measurements performed by
phase analysis light scattering using ZetaSizer Nano ZS
ZEN3600 (Malvern, UK) equipment. The mean hydro-
dynamic particle size of Magh-Rh2(H2cit)4 was deter-
mined in water by dynamic laser light scattering (DLS)
and the correlation functions were evaluated by cumu-
lant analysis. Maghemite nanoparticles were dispersed in
an electrolyte (0.005 molL-1 NaCl) solution to get a
0.05 molL-1 iron content.
Moreover, to determine the nanoparticles’ shape and
size by transmission electron microscopy (TEM) an ali-
quot (10 μL) of synthesized (Magh-Rh2(H2cit)4) (0.2%)
and Lip-Magh-Rh2(H2cit)4 (0.4%) was deposited on a
copper grid (300 mesh), previously covered with For-
mvar (0.7%), and dried at room temperature. It was
then observed under transmission electron microscopy
(TEM, JEOL 1011, 100kV) and the images were cap-
tured by a Gatan Ultrascan camera. Nanoparticles (n =
370) were measured by Image Pro-Plus 5.1 software and
data were adjusted by log normal distribution to obtain
the modal diameter.
• Synthesis of the Rhodium (II) Citrate Complex, Rh2(H2cit)4
Firstly, an aqueous solution of rhodium (II) trifluoroace-
tate (c.a. 1 mmol) was slowly added to a solution of citric
acid (c.a.10 mmol) in water under stirring and heated to
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70°C. The solvent was reduced almost to dryness fol-
lowed by addition of water, and this process was repeated
four times. The product was dissolved in methanol and
precipitated with petroleum ether and acetone 50:50 (v/
v). The solid was washed with ethyl acetate about twenty
times to eliminate the excess of ligand.
Yield: 20%. Anal. Calc for [Rh2(C6H8O7)4(H2O)2]: C,
28.64; H 3.2; Rh, 20.4; H2O, 3.5%. Found: C, 28.5; H,
3.6; Rh, 20.8; H2O, 4.41%. IR (KBr): ν(COOH) 1724s; νas
(CO2) 1598vs; νs(CO2) 1411vs cm
-1. ESI-MS (m/z) for
[Rh2(C6H7O7)4+H]
+: 970.8. 13C NMR: gC (125.75 MHz,
D2O) ppm: 46.3 (CH2); 76.3 (C-OH); 176.4 (CO2H)b;
179.8 (CO2H)a; 192.9 (Rh-CO2)b; 195.3 (Rh-CO2)a. UV-
vis (H2O, nm): 586 (π*(RhRh) ®s*(RhRh)); 442 (π*(RhRh)
®s*(RhO)); 292 (s(RhO) ®s*(RhRh)).
• Preparation of maghemite nanoparticles functionalized
with Rhodium Compound, Magh-Rh2(H2cit)4
Maghemite (g-Fe2O3) nanoparticles were prepared
according to procedures described previously [49]. Mag-
netite (Fe3O4) nanoparticles were synthesized by mixing
FeCl2 and FeCl3 aqueous solutions (2:1 molar ratio)
with NaOH solution under vigorous stirring. The solid
was washed with distilled water until pH = 9 and oxida-
tion of magnetite to maghemite was performed adjust-
ing the pH to 3, stirring the dispersion under heating
and constant oxygen flow. The reddish sediment was
centrifuged, dispersed in water, and dialyzed for
24 hours.
In the second stage of the nanocomposite preparation
procedure, the magnetic nanoparticles were functiona-
lized with rhodium (II) citrate. For this purpose, 5 mL
of the magnetic dispersion and 1 mL of rhodium (II)
citrate solution (0.054 molL-1) were mixed and stirred
for two hours at room temperature. The nanoparticles
were separated by centrifugation (5000 rpm), washed
three times with deionized water and thereafter dis-
persed in 5 mL of water. The stable magnetic solution
containing Magh-Rh2(H2cit)4 nanoparticles was obtained
by adjusting the pH to 7.
• Preparation and characterization of Magnetoliposomes
A small unilamellar liposome based on L-a-phosphatidyl-
choline and L-a-lysophosphatidylcholine was made
according to the modified injection method described else-
where [28]. We used L-a-lysophosphatidylcholine because
the formed vesicles are smaller and this leads to an
increase in the permeability of the liposomal formulation
through the cells [50]. Basically, 360 μL of an ethanolic
solution containing 0.686 mM L-a-phosphatidylcholine,
0.0137 mM L-a-lysophosphatidylcholine, was injected
with a syringe into 5 mL phosphate buffer solution (PBS),
pH 7.4. The injection of 262 μL of maghemite nanoparti-
cles with rhodium (II) citrate into PBS was performed at
56°C, under magnetic stirring at a flow rate 1 μL/s to a
final concentration of 1.96 × 1015 particle/mL.
Particle size and size distribution were obtained by
laser light scattering using a particle size analyzer (Zeta-
sizer, Malvern, UK). The magnetoliposome suspension
containing the maghemite nanoparticles (Magh-Rh2
(H2cit)4) was analyzed in a 1.0 cm quartz cell. The
measurement was performed in triplicates (n = 3).
All experiments were carried out at 25°C in the range of
100-2000 Hz.
• Cell culture
MCF-7 human mammary carcinoma cell line (purchased
from American Type Collection, ATCC, USA) and 4T1
murine mammary carcinoma cells (provided by Dr.
Suzanne Ostrand-Rosenberg, Maryland, USA) were cul-
tured in flasks (TPP, Switzerland) with Dulbecco’s Mod-
ified Eagle’s Medium (DMEM-Sigma, USA) containing
1% (v/v) penicillin-streptomycin (Sigma) and 10% (v/v)
heat-inactivated fetal bovine serum (FBS-Gibco). Human
normal breast cell line MCF-10A (donated by Dr. Maria
Mitzi Brentani, USP, Brazil) was cultured with a 1:1
mixture of DMEM and F12 medium (Sigma) supple-
mented with 5% horse serum (Gibco), hydrocortisone
(0.5 μg/mL, Sigma), insulin (1 mg/mL, Sigma), epider-
mal growth factor (20 ng/mL, Sigma), choleric toxin
(100 ng/mL, Sigma) and 1% (v/v) penicillin-streptomy-
cin. Cells were maintained at 37°C in humidified atmo-
sphere with 5% CO2.
• Cell treatment
Cells were seeded into 6 or 96 well culture microplates
at a density of 1.4 × 104 cells/cm2 and incubated for
24 h to allow cell’s adhesion. Then cells were incubated
with free Rh2(H2cit)4 (50-600 μM), Magh-Rh2(H2cit)4,
and Lip-Magh-Rh2(H2cit)4 (50 μM of Rh2(H2cit)4) for
24, 48, and 72 h. As negative control, cells were incu-
bated with maghemite nanoparticles and magnetolipo-
somes without Rh2(H2cit)4 at the same equimolar iron
concentrations found in Magh-Rh2(H2cit)4 (23 mM, 3 ×
1015 iron particles/mL) and Lip-Magh-Rh2(H2cit)4 (94.5
mM, 12.5 × 1015 iron particles/mL), respectively.
Untreated cells correspond to the control group, while
cells treated with paclitaxel, a chemotherapy widely used
in clinics, represent the positive control used to validate
the model cells. An equimolar dose of Rh2(H2cit)4 was
used in the treatment of cells with paclitaxel (50 micro-
molar) to compare their cytotoxicity. Dimethyl sulfoxide
(DMSO) was used as the paclitaxel treatment control.
• Cell viability assay
Cell viability was estimated by MTT (Invitrogen, USA)
assay. After treatment, as described above, cells were
incubated with 15 μL of MTT (5 mg/mL) and 185 μL of
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culture medium for two and half hours at 37°C in humi-
dified atmosphere with 5% CO2. Then the culture solu-
tion was removed and 200 μL of DMSO was added. The
absorbance readings were performed by spectrophot-
ometer (SpectraMax M2, Molecular Devices) using a
microplate reader at a 595 nm wavelength. The relative
cell viability (%) was calculated by the formula: [A]treat-
ment/[A]control ×100, where [A]treatment is the absor-
bance of the tested sample and [A]control is the
absorbance of control sample (containing only culture
medium).
• Cell morphology and ultra-structural analysis
The morphology and ultra-structural analysis were carried
out after 48 h of treatment with free Rh2(H2cit)4 (50 and
500 μM). Cell morphology was visualized by AxioSkop
light microscope (Zeiss, Germany) and images were cap-
tured using AxioVision (Zeiss) software. For ultra-struc-
tural analysis, cells were washed with PBS and fixed for 1
h in solution containing 2% glutaraldehyde (v/v), 2% (w/v)
paraformaldeyde, and 3% (w/v) sucrose in 0.1 M sodium
cacodylate buffer pH 7.2. Afterward, cells were rinsed in
the same buffer and post fixed, for 40 minutes, in 1%
osmium tetroxide (w/v) and 0.8% potassium ferricyanide
(10 mM CaCl2 in 0.2 M sodium cacodylate buffer). The
material was washed in distilled water and the block
stained was performed for 12 h with 0.5% uranyl acetate at
4°C. Then samples were dehydrated in a graded acetone
series (50-100%) for 10 minutes each and embedded in
Spurr resin. Ultrathin sections were observed in a Jeol®
1011 transmission electron microscope (MET) at 80 kV.
• Annexin-V/propidium iodide staining analysis
After treatments with 50 and 500 μM of free Rh2(H2cit)
4, cells (1 × 10
6 cels/mL) were washed with PBS and
resuspended in the solution containing 100 μL of bind-
ing buffer (10 mM of HEPES/NaOH (pH 7.4), 140 mM
NaCl, 2.5 mM CaCl2), 5 μL of anexina-V-FITC (Bio-
source, USA) and propidium iodide (5 μg/mL, Invitro-
gen). In this step, cells were incubated for 15 minutes in
the dark at room temperature. Next, 400 μL of binding
buffer were added to the cells and 10,000 events for
each sample were acquired by flow cytometry (Becton &
Dickenson, San Jose, CA-USA). After acquisition, the
analysis was done by software Cell QuestTM. Cells
without staining with annexin and propidium iodide (PI)
were used as negative control of fluorescence.
• Actin filaments and nucleus staining analysis
Firstly, poly-L-lysine (1%) was added to coverslips placed
in six well culture microplates and incubated overnight
at 4°C. Cells were then attached to coverslips and, after
48 h of treatments with free Rh2(H2cit)4 (50 and 500
μM), they were washed with PBS and fixed with 3.5%
paraformaldehyde for ten minutes at room temperature
(RT). Next, the cells were permeabilized with 0.1%
Triton-PBS for three minutes, washed with PBS, and
incubated with 1% bovine serum albumin (BSA) for
30 minutes. Subsequently, the cells were stained with
solution containing 2.5% Phaloidin-Alexa-Fluor 488 and
1% BSA (v/v) for 20 minutes and, after this time, 1 μg/
mL of DAPI (4’,6-diamidino-2-fenilindol) was added to
cells for seven minutes in the dark at RT. The cells
were washed twice with water, five minutes each, and
then the coverslips were placed in slides with 4% N-pro-
pil galate. Afterwards, the cells were examined and
images were captured by laser scanning confocal micro-
scopy (Leica SP5). All microscopy gain and offset set-
tings were maintained constant throughout the study.
• Statistical Analysis
To determine the difference in the cell line’s viability
and in the annexin-V/propidium iodide staining among
treatment groups over treatment time and cell line, an
analysis of variance (ANOVA) with general linear model
procedure followed by post hoc Tukey or Dunnet’s test
was used. Data were presented as mean value ± SEM of
at least two independent experiments (SPSS, Inc.,
Chicago, IL, version 17.0). The IC50 or EC50 values and
their 95% confidence intervals (CI 95%) were obtained
by nonlinear regression (Sigma Stat; Prism 5.0; Graph-
Pad Software Inc., San Diego, CA). The significance
level was set at p < 0.05. In order to characterize the
nanoparticles’ size and morphology, the experimental
data were fitted to a curve using a log-normal distribu-
tion function, and the modal diameter was obtained
(SPSS, Inc., Chicago, IL, version 17.0).
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